Generic Mestinon Availability
MESTINON (pyridostigmine bromide - injectable;injection)
MESTINON (pyridostigmine bromide - syrup;oral)
MESTINON (pyridostigmine bromide - tablet, extended release;oral)
Manufacturer: VALEANT PHARMS LLC
Approved Prior to Jan 1, 1982
Strength(s): 180MG [RLD]
MESTINON (pyridostigmine bromide - tablet;oral)
Has a generic version of Mestinon been approved?
Yes. The following products are equivalent to Mestinon:
Approval date: December 26, 2002
Strength(s): 60MG [AB]
Manufacturer: IMPAX LABS
Approval date: April 24, 2003
Strength(s): 60MG [AB]
Note: No generic formulation of the following products are available.
- pyridostigmine bromide - syrup;oral
- pyridostigmine bromide - tablet, extended release;oral
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mestinon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
There are no current U.S. patents associated with Mestinon.
- Mestinon Consumer Information (Wolters Kluwer)
- Mestinon controlled-release tablets Consumer Information (Wolters Kluwer)
- Mestinon syrup Consumer Information (Wolters Kluwer)
- Mestinon tablets Consumer Information (Wolters Kluwer)
- Mestinon Consumer Information (Cerner Multum)
- Pyridostigmine Consumer Information (Wolters Kluwer)
- Pyridostigmine controlled-release tablets Consumer Information (Wolters Kluwer)
- Pyridostigmine syrup Consumer Information (Wolters Kluwer)
- Pyridostigmine tablets Consumer Information (Wolters Kluwer)
- Pyridostigmine Consumer Information (Cerner Multum)
- Pyridostigmine Bromide AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|
|AB||Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.|
|AP||Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.|